Baxter International (BAX)
(Delayed Data from NYSE)
$40.13 USD
-0.10 (-0.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.16 +0.03 (0.07%) 7:46 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.13 USD
-0.10 (-0.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $40.16 +0.03 (0.07%) 7:46 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View
by Zacks Equity Research
Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low
by Zacks Equity Research
Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.
Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.
Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.
Pacific Biosciences (PACB) Loss Wider Than Expected in Q1
by Zacks Equity Research
Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.
Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.
Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.
CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow
by Zacks Equity Research
CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.
AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.
NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.
3 Reasons Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) gains ground on strategic buyouts and a raised guidance for 2018.
Baxter (BAX) Beats on Q1 Earnings & Revenues, Raises '18 View
by Zacks Equity Research
Solid performance in Renal Products, Medication Delivery, Pharmaceutical and Other segment boost Baxter's (BAX) Q1 results.
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) gains from strong domestic and international sales in Q1. A raised guidance buoys optimism.
Medical Product Stock Earnings Roster for Apr 26: BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
Can CAG Growth for IDEXX (IDXX) Stock Return in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) might repeat its gain streak in CAG for Q1, earlier driven by strong double-digit growth in reference labs and consumables plus a high-single-digit rise in rapid assay sales.
Can Hologic (HOLX) Diagnostics Growth Recur in Q2 Earnings?
by Zacks Equity Research
A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.
Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
by Zacks Equity Research
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics
by Zacks Equity Research
Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics
4 Top Stocks to Buy With Superb Efficiency Level
by Tirthankar Chakraborty
Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts
by Zacks Equity Research
Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.
Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK
by Zacks Equity Research
Baxter (BAX) steadily focuses on improving its Advanced Surgery business.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).